



SHAREABLE PDF

# Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”

Kevin K. Brown<sup>1</sup>, Rozsa Schlenker-Herceg<sup>2</sup> and Athol U. Wells<sup>3</sup>

**Affiliations:** <sup>1</sup>Dept of Medicine, National Jewish Health, Denver, CO, USA. <sup>2</sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. <sup>3</sup>National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK.

**Correspondence:** Kevin K. Brown, Dept of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA. E-mail: brownk@njhealth.org



@ERSpublications

**No set of criteria will cover all patients, but the inclusion criteria used in the INBUILD trial were effective at identifying a population of patients with progressive ILD** <https://bit.ly/3mKkzzi>

**Cite this article as:** Brown KK, Schlenker-Herceg R, Wells AU. Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”. *Eur Respir J* 2020; 56: 2003967 [<https://doi.org/10.1183/13993003.03967-2020>].

This single-page version can be shared freely online.

*Reply to Y.P. Moodley and co-workers:*